A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model

Therapeutic success of targeted therapy with BRAF inhibitors (BRAFi) for melanoma is limited by resistance development. Observations from preclinical mouse models and recent insights into the immunological effects caused by BRAFi give promise for future development of combination therapy for human m...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Cancer
Hlavní autoři: Bellmann, Lydia, Cappellano, Giuseppe, Schachtl‐Riess, Johanna F., Prokopi, Anastasia, Seretis, Athanasios, Ortner, Daniela, Tripp, Christoph H., Brinckerhoff, Constance E., Mullins, David W., Stoitzner, Patrizia
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
Tumor Immunology and Microenvironment
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7003881/
https://ncbi.nlm.nih.gov/pubmed/31702822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32777
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky